By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...
Pfizer made one thing clear this week: It's officially back in the obesity race.
CHMP is reviewing avacopan, a drug authorized in the EU for treating adults with severe, active granulomatosis with polyangiitis or microscopic polyangiitis.
Digital twins revolutionize drug discovery by integrating AI and biological data, enhancing prediction, trial design, and decision-making in precision medicine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results